Prospective observation for seven-year's highly active antiretroviral therapy in Chinese HIV-1 infected patients

Current HIV Research

Volumn 9, Issue 3, 2011, Pages 160-165

  He, Mei ^a   Zheng, Yu Huang ^a   Zhou, Hua Ying ^a   Mamadou, Diallo ^a   Chen, Zi ^a   Chen, Xia ^a   Yao, Yun Hai ^a   He, Yan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Acquired immunodeficiency syndrome; China; Efficacy; Highly active antiretroviral therapy; Long term; Safety

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ALLERGIC RASH; ALOPECIA; ANEMIA; ARTICLE; BLOOD CELL; BONE MARROW TOXICITY; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DROWSINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INSOMNIA; JAUNDICE; LACTIC ACIDOSIS; LEUKOPENIA; LIPID BLOOD LEVEL; LIPODYSTROPHY; LIVER FUNCTION; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAUSEA; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PROSPECTIVE STUDY; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; VOMITING;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD CHEMICAL ANALYSIS; CHINA; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; T-LYMPHOCYTE SUBSETS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 79959318880     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016211795945241     Document Type: Article

References (16)

1. Zhang CY, Chen J, Zheng YH, et al. Efficacy and toxicity observation for highly active antiretroviral therapy in two years. Chi J Med 2006; 45(6): 494-6.
2. Zheng YH, Chen J, Lei JH, et al. Immunological changes in HIV-1-infected patients treated with highly active antiretroviral therapy. Chi J Dermatol 2006; 39 (5): 42-6.
3. Zhou HY, Zheng YH, Zhang CY, et al. Evaluation of human immunodeficiency virus type 1-infected Chinese patients treated with highly active antiretroviral therapy for two years. Viral Immunol 2007; 20: 180-7.
4. Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. Aids 2003; 17: 1907-15.
5. Center of Diseases Prevention and Control of China: Guideline of free antiviral therapy for HIV-AIDS in China, Beijing, 2008.
6. Hua-ying Zhou, Yu-huang Zheng, Yan He, et al. Evaluation of 6_year highly active antiretroviral therapy in Chinese HIV-1 infected patients. Intervirology 2010; 53: 240-6.
7. Tarwater PM, Margolick JB, Jin J, et al. Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J AIDS 2001; 27: 168-75.
8. Health Ministry of China, WHO, UNAIDS:" AIDS Yearly Report, 2009". Shanghai, 2009.11.30.
9. Resino S, Resino R, Micheloud D, et al. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Clin Inf Dis 2006; 42: 862-9.
10. Evan W, Viviane DL, Robert SH, et al. Highly Active Antiretroviral Therapy and survival in HIV-infected injection drug users. JAMA 2008; 300(5): 550-4.
11. Kunjal P, Miguel AH, Paige LW, et al. Long-Term Effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-Year follow-up study. Clin Inf Dis 2008; 46: 507-15.
12. Ma Y, Zhao DC, Yu L, et al. Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China. Clin Inf Des 2010; 50: 264-72.
13. Michael G and Sension, MD. Long-term suppression of HIV infection: benefits and limitations of current treatment options. J Association of Nurses in AIDS Care 2007; 18: S2-S10.
14. Granich R, Crowley S, Vitoria M, et al. Highly active antiretroviral treatment for the prevention of HIV transmission. J Int AIDS Soc 2010; 13(1): 1-4.
15. Yuan HL, Zheng YH, Zhou HY, et al. Research on HIV-1 pol mutation and viral resistance in Hunan, China. Chi J Inf Contrl 2008; 7: 5-8.
16. Li Y and Zheng YH. Clinical analysis and curative effect of opportunity infection in 100 AIDS patients. Chi J Inf Control 2007; 6(5): 311-5.